- September 3, 2022
- Newsletter
- 617-430-5616
Menu
» Home » CAD » Endocrinology » Metabolic Disorders » Type II Glycogen Storage Disease (Pompe Disease)
ADVERTISEMENT
ADVERTISEMENT
» Home » CAD » Endocrinology » Metabolic Disorders » Type II Glycogen Storage Disease (Pompe Disease)
Background
Epidemiology
Anatomy
Pathophysiology
Etiology
Genetics
Prognostic Factors
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Indicated for late-onset Pompe disease:
≥30kg: 20mg/kg intravenous every two weeks
Dose Adjustments
Hypersensitivity reactions
Severe hypersensitivity (including anaphylaxis) or severe infusion-associated reaction (IAR): Immediately discontinue and implement appropriate medical treatment
Mild-to-moderate
• Consider temporarily holding or slowing the infusion rate and initiating appropriate medical treatment as follows
• If symptoms persist, wait at least 30 minutes for symptoms to resolve before stopping infusion for the day
• If symptoms subside, resume infusion for 30 minutes by decreasing the rate to 50% at which the reaction occurred, and subsequently increase the infusion rate by 50% for 15-30 minutes; if symptoms do not recur, increase infusion rate to rate at which the reaction occurred and consider continuing to increase in a stepwise manner
• This information pertains to managing mild-to-moderate and severe hypersensitivity or severe infusion-associated reactions (IAR) to a medication administered through an infusion
• In case of a severe hypersensitivity reaction (including anaphylaxis) or severe IAR, the infusion should be immediately discontinued, and appropriate medical treatment should be initiated
In mild-to-moderate reactions, the infusion rate should be temporarily held or slowed down, and appropriate medical treatment should be initiated. If symptoms persist, the infusion should be stopped for the day and resumed the next day after a waiting period of at least 30 minutes. If symptoms subside, the infusion rate should be gradually increased stepwise, starting with a 50% reduction in the rate at which the reaction occurred. If symptoms do not recur, the infusion rate can be gradually increased until it reaches the rate at which the reaction occurred
Indicated for late-onset Pompe disease
:
<30kg: 40mg/kg intravenous every two weeks
≥30kg: 20mg/kg intravenous every 2 weeks
Dose Adjustments
Hypersensitivity reactions
In case of severe hypersensitivity or severe infusion-associated reaction, the infusion should be immediately discontinued, and appropriate medical treatment should be initiated. Consider temporarily holding or slowing the infusion rate and initiating appropriate medical treatment for mild to moderate reactions. If symptoms persist, wait for at least 30 minutes for symptoms to resolve before discontinuing the infusion for the day. If symptoms subside, the infusion rate can be resumed, decreased by 50%, and then gradually increased over time to monitor for the recurrence of symptoms
Future Trends
References
ADVERTISEMENT
» Home » CAD » Endocrinology » Metabolic Disorders » Type II Glycogen Storage Disease (Pompe Disease)
Indicated for late-onset Pompe disease:
≥30kg: 20mg/kg intravenous every two weeks
Dose Adjustments
Hypersensitivity reactions
Severe hypersensitivity (including anaphylaxis) or severe infusion-associated reaction (IAR): Immediately discontinue and implement appropriate medical treatment
Mild-to-moderate
• Consider temporarily holding or slowing the infusion rate and initiating appropriate medical treatment as follows
• If symptoms persist, wait at least 30 minutes for symptoms to resolve before stopping infusion for the day
• If symptoms subside, resume infusion for 30 minutes by decreasing the rate to 50% at which the reaction occurred, and subsequently increase the infusion rate by 50% for 15-30 minutes; if symptoms do not recur, increase infusion rate to rate at which the reaction occurred and consider continuing to increase in a stepwise manner
• This information pertains to managing mild-to-moderate and severe hypersensitivity or severe infusion-associated reactions (IAR) to a medication administered through an infusion
• In case of a severe hypersensitivity reaction (including anaphylaxis) or severe IAR, the infusion should be immediately discontinued, and appropriate medical treatment should be initiated
In mild-to-moderate reactions, the infusion rate should be temporarily held or slowed down, and appropriate medical treatment should be initiated. If symptoms persist, the infusion should be stopped for the day and resumed the next day after a waiting period of at least 30 minutes. If symptoms subside, the infusion rate should be gradually increased stepwise, starting with a 50% reduction in the rate at which the reaction occurred. If symptoms do not recur, the infusion rate can be gradually increased until it reaches the rate at which the reaction occurred
Indicated for late-onset Pompe disease
:
<30kg: 40mg/kg intravenous every two weeks
≥30kg: 20mg/kg intravenous every 2 weeks
Dose Adjustments
Hypersensitivity reactions
In case of severe hypersensitivity or severe infusion-associated reaction, the infusion should be immediately discontinued, and appropriate medical treatment should be initiated. Consider temporarily holding or slowing the infusion rate and initiating appropriate medical treatment for mild to moderate reactions. If symptoms persist, wait for at least 30 minutes for symptoms to resolve before discontinuing the infusion for the day. If symptoms subside, the infusion rate can be resumed, decreased by 50%, and then gradually increased over time to monitor for the recurrence of symptoms
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.